Our latest survey of #biopharma professionals on #DigitalTransformation in the industry uncovered a hype-actual adoption gap.
Get the full industry report at https://t.co/xZJqIJbLID
#AI
@FDACBER’s draft guidance on gene therapy and genome editing may transform CMC and data strategies for biopharma. How is your team preparing for these regulatory changes? Learn more: https://t.co/RyEtO2QB75
#GeneTherapy#CGT#RegulatoryAffairs
Switzerland Innovation Park Main Campus is advancing biopharma with integrated biomedical engineering and 3D-printed solutions. Explore Dr. Johannes Eisenhut’s insights on global R&D impact: https://t.co/PljaGup7hG
#BiopharmaInnovation#RegenerativeMedicine#3DPrinting
@bmsnews with Biokin's SystImmune report promising interim phase 3 results for the EGFRxHER3 bispecific ADC, iza-bren, which met OS and PFS endpoints in TNBC and ESCC phase 3 trials. How does this impact oncology care? Learn more: https://t.co/dNUnir2aI0
#CancerTrials#Oncology
Integrated drug development models are helping biopharma teams reduce tech-transfer risk, eliminate delays, and accelerate complex biologics from discovery to clinic. #Biologics
https://t.co/qIGUnaOLTG
Dual PD-L1/VEGF-A blockade with pumitamig plus chemo shows high response and 100% disease control in advanced NSCLC. Could this set a new standard? Learn more: https://t.co/cHiRi1aycj
@BioNTech_Group@bmsnews#NSCLC#ImmunoOncology
Fosun Pharma and @tevapharm have dosed the first patient in China with FXB0871, a novel PD-1 targeted IL-2 fusion protein. Could this advance the future of combination immunotherapy? Learn more: https://t.co/Td628NDPu1
#ImmunoOncology#CancerResearch#BiotechNews
Successful tech transfer starts with alignment, risk management, and process precision—Rentschler BioPharma’s dual-site model helps accelerate timelines while ensuring quality and manufacturing flexibility. #Biomanufacturing
https://t.co/6rmKT0BM3I
Strategic investments in manufacturing and supply chains are unlocking faster, more reliable, and higher-quality delivery—while enabling global agility at scale. #OperationalExcellence
https://t.co/2XFt2ojK7f
https://t.co/5zjDLrMiXX
@biohub has unveiled an open-source AI model to advance protein design for cancer and immune therapies. Will this reshape biopharma R&D? Explore the impact: https://t.co/V88IZeJlPf
#AIDrugDiscovery#ProteinDesign#Bioinformatics
@swissinnova Basel’s life sciences hub is transforming as global leaders and startups drive innovation across the biopharma value chain. Discover insights from SENN Development's Dr. Johannes Eisenhut: https://t.co/MrEimXliVM
#LifeSciences#BiotechEcosystem#Innovation
Unlock complete analytical workflows for GLP-1 therapeutics—ensuring purity, stability, and compliance across development and QC: https://t.co/nefjELWvkd #Biopharma
Olezarsen (Tryngolza; Sobi and @ionispharma)
cut triglycerides by 66% and acute pancreatitis risk by 85% in severe hypertriglyceridemia. What could this mean for future payer decisions? Learn more: https://t.co/GmSI449APv
#hypertriglyceridemia#RNAtherapy#pancreatitis
Scalable, modular manufacturing and AI-driven automation are transforming CGT production, according to @CRiverLabs' Dr. Alan Smith. How is your team integrating flexibility and AI in CGT manufacturing? Learn more: https://t.co/zbH6axV9IX
#CellAndGeneTherapy#Biomanufacturing
Can 3D neural microtissues redefine cell therapy for Parkinson’s? @treefrogtx unveils new preclinical data on TFG-001’s dopamine release and reinnervation. Learn more: https://t.co/nO6N0aSY9r
#Parkinsons#CellTherapy#RegenerativeMedicine
Designing safe cleaning validation for highly potent ADCs? Paul Lopolito of #STERIS highlights the importance of HBELs, degradation data, and risk-based strategies. Explore his insights: https://t.co/rpmyCPYwRe
#ADC#CleaningValidation#Biopharma
@BioMarin's vosoritide shows significant growth gains in children with hypochondroplasia in the Phase 3 CANOPY-HCH-3 study. Could this reshape care for FGFR3-related skeletal dysplasia? Read more: https://t.co/gqxlaaRlYi
#Hypochondroplasia#RareDiseaseResearch
@AvaiBio and @AustrianovaST mark a major milestone in α-Klotho cell therapy with a GMP master cell bank for Cell-in-a-Box. Next: viral testing. How do you track early CMC progress? Read more: https://t.co/dlttd0uUYm
#CellTherapy#GeneTherapy#HealthyAging
inSPECt™ MS is advancing HCP profiling with native digestion and LC-MS analysis—delivering sensitive, low-ppm quantification to support safer, more effective biopharmaceuticals. #Bioprocessing
https://t.co/BojLk9ye9u